BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30119215)

  • 21. Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
    Lin J; Zuo J; Cui Y; Song C; Wu X; Feng H; Li J; Li S; Xu Q; Wei W; Qiu G; He H
    Oncol Rep; 2018 May; 39(5):2333-2341. PubMed ID: 29565460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
    Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
    Zeng H; Xu N; Liu Y; Liu B; Yang Z; Fu Z; Lian C; Guo H
    Int J Oncol; 2017 Aug; 51(2):445-455. PubMed ID: 28714520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
    Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
    Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
    Borges KS; Castro-Gamero AM; Moreno DA; da Silva Silveira V; Brassesco MS; de Paula Queiroz RG; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):405-14. PubMed ID: 22160182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
    Zhang L; Wang H
    Pharmacol Rep; 2017 Dec; 69(6):1186-1193. PubMed ID: 29128799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
    Fu T; Yang Y; Mu Z; Sun R; Li X; Dong J
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):680-692. PubMed ID: 34435542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
    Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
    Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
    Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
    Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
    Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
    Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.